Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double‑blind trial of ticagrelor + low‑dose aspirin versus clopidogrel + low‑dose aspirin in Asian/Japanese ACS patients planned for PCI
jRCT2080221435Phase 3
- Sponsor
- AstraZeneca
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ticagrelor in acute coronary syndrome (ACS) (2 arms), sponsored by AstraZeneca.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on jRCT2080221435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221435.